NEGXF (NexgenRx) Other Financing: $0.00 Mil (TTM As of Mar. 2026)


NEGXF NexgenRx Inc NEGXF
40 GF Score
Price $0.33
GF Value $0.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx Other Financing?

NexgenRx NEGXF 40 Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

NexgenRx's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

NexgenRx's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

NexgenRx Other Financing Historical Data

* Premium members only.

The historical data trend for NexgenRx's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx Other Financing Chart

NexgenRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 0.00

NexgenRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NEGXF
40GF Score
NexgenRx Inc NEGXF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexgenRx Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
NexgenRx (NEGXF) has a Other Financing of $0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NexgenRx and its competitors.
Is NexgenRx's Other Financing too high?
NexgenRx's current Other Financing is $0.00 Mil. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Other Financing compare to VEEV and BTSG?
NexgenRx's Other Financing of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NexgenRx and its competitors. NexgenRx's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.33 — trading 47.7% above its estimated fair value. The current Other Financing is $0.00 Mil. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 47.7% above its estimated GF Value™ of $0.22. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • Other Financing: $0.00 Mil
  • GF Value™: $0.22 vs. price of $0.33 (47.7% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score

Get the complete analysis for NEGXF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.22
GF Value